Patents by Inventor Srdjan R. Stankovic

Srdjan R. Stankovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
    Patent number: 11464768
    Abstract: Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin. Also provided herein are methods for the treatment of delusions and/or hallucinations in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing NPI-NH score in a human with Alzheimer's Disease comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing agitated behavior or aggressive behavior in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 11, 2022
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Bruce Duane Coate, James Randall Owen, Mark Donald Knowles, Srdjan R. Stankovic, James M. Youakim
  • METHODS OF TREATING DEPRESSION, ANXIETY AND SEXUAL DYSFUNCTION USING THE COMPOUND PIMAVANSERIN
    Publication number: 20220016101
    Abstract: The disclosure provides, in part, a method of treating anxious distress with major depressive disorder in a patient in need thereof, comprising administering to the patient N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N?-(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof. Also provided herein is a method of treating depression in a patient in need thereof, wherein the patient is also suffering from Parkinson's disease, comprising orally administering to the patient 34 mg of N-(4-fluorophenylmethyl)-N-1-methylpiperidin-4-yl)-N?-(4-(2-methylpropyloxy)phenylmethyl)carbamide once daily, as well as methods for the treatment of a SSRI or SNRI-induced sexual dysfunction in a human subject.
    Type: Application
    Filed: October 30, 2019
    Publication date: January 20, 2022
    Applicant: ACADIA Pharmaceuticals Inc.
    Inventors: Ethan S. Burstein, Srdjan R. Stankovic, Bryan Dirks, Maurizio Fava, James Randall Owen, Daryl DeKarske
  • PIMAVANSERIN ALONE OR IN COMBINATION FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE PSYCHOSIS
    Publication number: 20200237739
    Abstract: Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin. Also provided herein are methods for the treatment of delusions and/or hallucinations in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing NPI-NH score in a human with Alzheimer's Disease comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing agitated behavior or aggressive behavior in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 14, 2017
    Publication date: July 30, 2020
    Inventors: Bruce Duane Coate, James Randall Owen, Mark Donald Knowles, Srdjan R. Stankovic, James M. Youakim